ArticleThe Australasian journal of dermatology2026
Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study.
Article in The Australasian journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND/
objectivesTo estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years.
methodsA cross-sectional survey was conducted from August to September 2024 in a quota-balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12-14 years). Participants completed the Alopecia Assessment Tool (ALTO) to identify AA. Participants with AA completed the Scalp Hair Assessment Patient-Reported Outcome to assess hair loss and a questionnaire on hair loss experience. Lifetime prevalence was calculated as the proportion of participants with AA per the ALTO, and point prevalence was calculated as the proportion of participants with AA per the ALTO and current scalp hair loss.
resultsOf 8,256 participants, 194 had potential AA, and of those, 188 were aged ≥ 15 years. The lifetime prevalence (95% CI) of AA among those aged ≥ 15 years ranged from 1.2% (1.08-1.32) to 2.3% (2.13-2.47), with a point prevalence (95% CI) of 0.9% (0.79-1.01) to 1.4% (1.27-1.53). Of 194 participants with potential AA, 125 had healthcare provider (HCP)-diagnosed AA and 69 had self-diagnosed AA. More self-diagnosed participants had active hair loss than HCP-diagnosed participants. Thirty-nine HCP-diagnosed participants (31.2%) were not using any treatment/management approach, and of those, 23.1% were unaware of treatment/management options. Most self-diagnosed participants were using shampoos/conditioners recommended for hair loss (62.3%).
conclusionsThere is a need for improved AA education in Australia to increase awareness, given that approximately 36% of participants were self-diagnosed and 31% of HCP-diagnosed participants were not using treatment or a management approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.